Glenmark Pharmaceuticals has informed that the US FDA has issued Form 483 with five observations after an inspection at the Company’s formulation manufacturing facility based out of Goa, India between May 12, 2022 and May 20, 2022.
The above information is a part of company’s filings submitted to BSE.